Safest Choice of Antihypertensive Regimen for Postpartum Hypertension
A phase 3 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 500 participants.
Also called NCT05551104
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; no masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 500 participants
- Sponsor
- Loma Linda University
- Registry
-
NCT05551104
-
- Started
- (actual)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- United States
- Registry status
- Recruiting
Technical summary
Registry record NCT05551104. Randomized; no masking; primary purpose treatment. Start 2023-05-08 (actual); primary completion 2027-12 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Safest Choice of Antihypertensive Regimen for Postpartum Hypertension
- Acronym
- SCARPH
- Condition
- Postpartum Complication
- Condition
- Maternal Hypertension
- Condition
- High Blood Pressure
- Intervention (Drug)
- Oral Nifedipine
- Intervention (Drug)
- Oral Labetalol
- Lead sponsor
- Loma Linda University
Record details
- Record id
cardio:ct-nct05551104- Content hash
752efe1dad4515ea4547ea9a6686d58ff306871bdba349fa5b14d39aab566f0f